| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
Emergency department visit for the evaluation and management, high severity |
20,542 |
17,640 |
$2.32M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
21,622 |
19,068 |
$2.02M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
11,435 |
8,353 |
$1.52M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
9,029 |
7,022 |
$654K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,993 |
1,699 |
$492K |
| 70450 |
Computed tomography, head or brain; without contrast material |
4,143 |
3,411 |
$375K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
5,066 |
4,074 |
$199K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
1,030 |
820 |
$165K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
2,191 |
1,922 |
$140K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,637 |
1,373 |
$109K |
| 80053 |
Comprehensive metabolic panel |
22,475 |
15,822 |
$102K |
| 36415 |
Collection of venous blood by venipuncture |
13,340 |
7,844 |
$85K |
| G0378 |
Hospital observation service, per hour |
9,070 |
3,374 |
$83K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,239 |
1,109 |
$64K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
25,868 |
16,993 |
$59K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
8,576 |
6,955 |
$59K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
8,011 |
5,497 |
$54K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,457 |
1,714 |
$54K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
10,371 |
7,226 |
$47K |
| 71045 |
Radiologic examination, chest; single view |
12,039 |
9,721 |
$40K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
4,349 |
2,733 |
$38K |
| 84484 |
|
7,805 |
4,268 |
$38K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
6,209 |
3,706 |
$35K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
1,894 |
999 |
$33K |
| 82948 |
|
7,273 |
2,310 |
$33K |
| 85027 |
|
3,753 |
2,367 |
$33K |
| 85007 |
|
2,790 |
1,862 |
$27K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
8,057 |
5,533 |
$26K |
| 71046 |
Radiologic examination, chest; 2 views |
5,710 |
5,049 |
$24K |
| 83690 |
|
7,271 |
5,913 |
$24K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
25,030 |
12,128 |
$24K |
| 96376 |
|
4,053 |
1,821 |
$23K |
| 94760 |
|
3,780 |
1,992 |
$23K |
| 85730 |
|
4,715 |
3,683 |
$22K |
| 85610 |
|
4,893 |
3,851 |
$22K |
| 76801 |
|
1,067 |
878 |
$21K |
| 81001 |
|
13,018 |
10,969 |
$21K |
| 87040 |
|
4,520 |
2,288 |
$20K |
| 81025 |
|
11,380 |
9,986 |
$19K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
356 |
334 |
$14K |
| 82550 |
|
3,884 |
2,783 |
$14K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
4,591 |
3,902 |
$13K |
| 83735 |
|
4,012 |
2,377 |
$12K |
| 81003 |
|
4,683 |
4,089 |
$11K |
| 83880 |
|
1,786 |
1,374 |
$11K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,702 |
2,417 |
$11K |
| 83605 |
|
2,036 |
1,372 |
$11K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
292 |
252 |
$11K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,369 |
1,650 |
$10K |
| 59025 |
Fetal non-stress test |
397 |
307 |
$10K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
410 |
366 |
$9K |
| 87077 |
|
2,150 |
1,795 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,630 |
1,377 |
$7K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,640 |
1,367 |
$6K |
| A9270 |
Non-covered item or service |
1,955 |
459 |
$6K |
| 87430 |
|
2,136 |
1,903 |
$5K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,292 |
1,912 |
$5K |
| 94664 |
|
526 |
365 |
$5K |
| 87186 |
|
1,638 |
1,337 |
$5K |
| 87807 |
|
4,675 |
4,138 |
$5K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
605 |
513 |
$5K |
| 87088 |
|
4,456 |
3,782 |
$5K |
| 93976 |
|
131 |
120 |
$5K |
| 73562 |
|
798 |
688 |
$5K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
412 |
318 |
$4K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
33 |
25 |
$4K |
| 86901 |
|
1,741 |
1,352 |
$4K |
| 93971 |
|
191 |
159 |
$4K |
| 86140 |
|
1,803 |
1,500 |
$4K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
302 |
265 |
$3K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
11,767 |
9,984 |
$3K |
| 85378 |
|
775 |
661 |
$3K |
| 73630 |
|
412 |
342 |
$3K |
| 84443 |
Thyroid stimulating hormone (TSH) |
655 |
502 |
$3K |
| J1815 |
Injection, insulin, per 5 units |
374 |
171 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
528 |
399 |
$3K |
| 73610 |
|
310 |
268 |
$3K |
| 84702 |
|
2,581 |
2,074 |
$3K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
215 |
169 |
$3K |
| 84703 |
|
607 |
539 |
$2K |
| 74018 |
|
529 |
468 |
$2K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
693 |
326 |
$2K |
| 10060 |
|
17 |
16 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,838 |
1,494 |
$1K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
650 |
597 |
$1K |
| 86900 |
|
927 |
700 |
$1K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
322 |
265 |
$1K |
| 96367 |
|
336 |
238 |
$1K |
| 76770 |
|
12 |
12 |
$1K |
| 86850 |
|
471 |
372 |
$1K |
| 76641 |
|
13 |
13 |
$1K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
50 |
43 |
$1K |
| 94010 |
|
30 |
13 |
$1K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
121 |
65 |
$1K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
20 |
17 |
$1K |
| 73030 |
|
162 |
146 |
$1K |
| 80061 |
Lipid panel |
348 |
267 |
$803.20 |
| 87070 |
|
1,602 |
1,403 |
$774.06 |
| 85379 |
|
498 |
385 |
$697.95 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
25 |
13 |
$690.05 |
| 87081 |
|
1,898 |
1,704 |
$684.92 |
| 73130 |
|
174 |
159 |
$673.95 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
654 |
601 |
$639.96 |
| 87210 |
|
377 |
338 |
$639.17 |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
228 |
75 |
$631.28 |
| 82728 |
|
198 |
151 |
$599.21 |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
33 |
27 |
$506.10 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
3,140 |
2,799 |
$483.25 |
| 82803 |
|
224 |
161 |
$413.61 |
| 72100 |
|
119 |
108 |
$344.83 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
145 |
116 |
$288.53 |
| 80076 |
|
479 |
374 |
$261.50 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
49 |
40 |
$256.00 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
143 |
127 |
$253.47 |
| G0379 |
Direct admission of patient for hospital observation care |
13 |
12 |
$244.15 |
| 83615 |
|
131 |
102 |
$219.58 |
| 82150 |
|
203 |
174 |
$213.43 |
| 93970 |
|
18 |
13 |
$178.68 |
| 86403 |
|
69 |
56 |
$176.48 |
| 84439 |
|
168 |
141 |
$157.39 |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
368 |
318 |
$126.75 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
284 |
228 |
$113.96 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
697 |
422 |
$99.93 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
234 |
187 |
$96.60 |
| 73590 |
|
13 |
12 |
$59.81 |
| 86706 |
|
20 |
13 |
$58.60 |
| 73502 |
|
14 |
12 |
$50.36 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
155 |
124 |
$28.77 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
216 |
167 |
$28.20 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
64 |
42 |
$20.16 |
| 80074 |
|
19 |
13 |
$19.83 |
| 84550 |
|
17 |
12 |
$8.01 |
| 85651 |
|
14 |
12 |
$7.88 |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
19 |
14 |
$5.34 |
| 86592 |
|
32 |
25 |
$5.10 |
| J7510 |
Prednisolone oral, per 5 mg |
488 |
420 |
$3.08 |
| 73080 |
|
14 |
13 |
$1.78 |
| 82270 |
|
13 |
13 |
$1.54 |
| 87581 |
|
14 |
13 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
16 |
12 |
$0.00 |
| 87486 |
|
14 |
13 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
14 |
13 |
$0.00 |
| 94761 |
|
19 |
12 |
$0.00 |
| 80143 |
|
16 |
12 |
$0.00 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
14 |
13 |
$0.00 |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
110 |
88 |
$0.00 |
| 84100 |
|
34 |
14 |
$0.00 |
| 73110 |
|
14 |
13 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
17 |
17 |
$0.00 |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
14 |
13 |
$0.00 |